Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
J Breast Cancer. 2013 Sep;16(3):274-84. doi: 10.4048/jbc.2013.16.3.274. Epub 2013 Sep 30.
This pilot study aimed to evaluate prognostic factors of postmastectomy radiotherapy (PMRT) for breast cancer patients undergoing systemic therapy in either preoperative or postoperative setting.
Between 2003 and 2009, 113 patients received PMRT: 61 underwent preoperative systemic therapy (PST subgroup) and 52 received postoperative systemic therapy (non-PST subgroup).
The median follow-up time was 72.3 months (range, 34.0-109.4 months) for surviving patients. In univariate analysis of all patients, disease-free survival (DFS) was associated with age, nodal ratio (NR), and Ki-67 expression; overall survival (OS) was associated with NR and Ki-67 expression. Pathologic N stage and HER2 expression were marginally associated with DFS and OS. In the non-PST subgroup, DFS was associated with age, NR, venous invasion, and Ki-67 expression; OS was associated with age. In the PST subgroup, DFS was associated with ypN stage and NR; OS was associated with ypN, histologic grade, HER2 expression, and p53 expression. In multivariate analysis of all patients, DFS and OS were significantly associated with NR (p=0.003 and p=0.019, respectively) and Ki-67 expression (p=0.002 and p=0.015, respectively). Patients were classified into low-risk (NR ≤0.2 and Ki-67 ≤20%; n=34), intermediate-risk (NR >0.2 or Ki-67 >20%; n=63), and high-risk (NR >0.2 and Ki-67 >20%; n=16) subgroups. All low-risk patients were alive at the time of analysis. High-risk (p<0.001 and p=0.001, respectively) and intermediate-risk (p=0.022 and p=0.008, respectively) patients had significantly shorter DFS and OS than low-risk patients. This prognostic model was statistically significant for DFS when applied to the PST (p=0.001) and non-PST (p=0.016) subgroups separately.
For breast cancer patients undergoing PMRT, NR and Ki-67 are potential prognostic factors. A model using these factors might help predict a poor prognosis. Whether NR and Ki-67 are also prognostic for different setting of systemic therapy, preoperative or postoperative, warrants further study.
本研究旨在评估接受系统治疗的乳腺癌患者行乳房切除术放疗(PMRT)的预后因素,这些患者接受系统治疗的时间分别为术前或术后。
2003 年至 2009 年间,113 例患者接受了 PMRT:61 例患者接受术前系统治疗(PST 亚组),52 例患者接受术后系统治疗(非-PST 亚组)。
生存患者的中位随访时间为 72.3 个月(范围,34.0-109.4 个月)。对所有患者进行单因素分析,无病生存(DFS)与年龄、淋巴结比值(NR)和 Ki-67 表达相关;总生存(OS)与 NR 和 Ki-67 表达相关。病理 N 期和 HER2 表达与 DFS 和 OS 有边缘相关性。在非-PST 亚组中,DFS 与年龄、NR、静脉侵犯和 Ki-67 表达相关;OS 与年龄相关。在 PST 亚组中,DFS 与ypN 期和 NR 相关;OS 与 ypN、组织学分级、HER2 表达和 p53 表达相关。对所有患者进行多因素分析,DFS 和 OS 与 NR(p=0.003 和 p=0.019)和 Ki-67 表达(p=0.002 和 p=0.015)显著相关。将患者分为低危组(NR≤0.2 和 Ki-67≤20%;n=34)、中危组(NR>0.2 或 Ki-67>20%;n=63)和高危组(NR>0.2 和 Ki-67>20%;n=16)。在分析时,所有低危组患者均存活。高危(p<0.001 和 p=0.001)和中危(p=0.022 和 p=0.008)患者的 DFS 和 OS 均显著短于低危患者。该预后模型对 PST(p=0.001)和非-PST(p=0.016)亚组的 DFS 均具有统计学意义。
对于接受 PMRT 的乳腺癌患者,NR 和 Ki-67 是潜在的预后因素。使用这些因素的模型可能有助于预测不良预后。NR 和 Ki-67 是否也是术前或术后不同系统治疗方案的预后因素,尚需进一步研究。